YD Bio Ltd
YDESHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, YD Bio Ltd focuses on Biotechnology services and products. YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet. The $250.7M market capitalization puts YDES squarely in micro-cap range for its industry. The company is based in Taipei, Taiwan.
Market Cap
$250.7M
Beta
-0.03
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$0.00
EPS (Fwd)
—
ROE
-42.7%
ROA
-25.4%
Cash
$3.1M
Total Debt
$22,265
Free CF
-$3.9M
52W Change
-77.0%
Annual Financials
Cash vs Debt
Where YDES stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, YDES finished 27.55% below its 150-day moving average ($5.19) and 45.19% below its 200-day moving average ($6.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is YDES overbought or oversold?
At the September 3, 2026 close, YDES's RSI(14) was 61.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.1M in cash and $22K in debt, YDES maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$3.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $350K (2023) to $597K (2025), reflecting a 70% increase over the period.
YDES's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence YD Bio Ltd's trajectory.